Related Experiment Video

Updated: Jun 14, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?

Wei-Chun Chen, Wei Chen, Guan-Chin Tseng

    Liver International : Official Journal of the International Association for the Study of the Liver
    |March 30, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
    13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Related Experiment Videos

    Last Updated: Jun 14, 2026

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
    13:34

    A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

    Published on: April 6, 2016

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Darunavir and Fosamprenavir Inhibit Zika Virus Replication via Dual Targeting of the Envelope Protein and NS2B-NS3 Protease.

    Journal of medical virology·2026

    Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.

    Liver cancer·2026

    Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.

    Liver cancer·2026

    Systemic Treatment Strategies for Recurrent Hepatocellular Carcinoma Following Liver Transplantation: A 20-y Retrospective Analysis With Clinical Insights.

    Transplantation·2026

    Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B.

    Annals of medicine·2026

    Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.

    Annals of transplantation·2026

    Ultrasound-Based Skeletal Muscle Assessment for Prognostication in Cirrhosis: A Systematic Review.

    Liver international : official journal of the International Association for the Study of the Liver·2026

    BBOX1 Deficiency Exacerbates Liver Fibrosis Through Carnitine Biosynthesis Disruption Rescued by Carnitine Supplementation.

    Liver international : official journal of the International Association for the Study of the Liver·2026

    Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2).

    Liver international : official journal of the International Association for the Study of the Liver·2026

    Multicenter Evaluation of Large Language Models Versus Hepatologists for Prognostic Prediction in Drug-Induced Liver Injury.

    Liver international : official journal of the International Association for the Study of the Liver·2026

    Prognostic Value of Liver Stiffness in Advanced Chronic Liver Disease After Hepatitis C Virus Eradication.

    Liver international : official journal of the International Association for the Study of the Liver·2026

    EuroHePP: The European Toolkit to Strengthen National Responses for the Elimination of Viral Hepatitis in Prisons.

    Liver international : official journal of the International Association for the Study of the Liver·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us